Zhou Xin, Du Yiping, Xu Jun, Huang Zebo, Qiu Tianzhu, Wang Xiaping, Qian Jiaqi, Zhu Wei, Liu Ping
Department of Oncology, First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, China.
Tumour Biol. 2014 Nov;35(11):11659-66. doi: 10.1007/s13277-014-2504-x. Epub 2014 Aug 20.
Recently, lymphocyte to monocyte ratio (LMR) has been reported to be associated with clinical outcomes in some types of cancer but has not been explored in gastric cancer. In this study, we analyzed the association between LMR and clinical outcomes in stage II/III gastric cancer patients. Preoperative LMR calculated from peripheral lymphocyte and monocyte with corresponding clinical features from 426 stage II/III gastric cancer patients was noted. Kaplan-Meier method and Cox regression model were applied for overall survival (OS) and recurrence-free survival (RFS). Related with smaller tumor size (p<0.001), increased LMR could predict better OS [hazard ratio (HR), 0.688; 95% confidence interval (CI), 0.521-0.908, p=0.008] and was borderline significantly associated with better RFS (HR, 0.775; 95% CI, 0.592-1.01, p=0.06) in stage II/III gastric cancer patients through multivariable analysis. Subgroup analyses revealed that except stage III patients for RFS which yielded borderline significance (p=0.052), lower LMR was associated with poor clinical outcomes for patients regardless of different stages or whether the patients received adjuvant chemotherapy. The elevated preoperative LMR level was a significant favorable factor in the prognosis of stage II/III gastric cancer patients, especially for those with stage II. However, further validation of our findings is warranted.
最近，有报道称淋巴细胞与单核细胞比值（LMR）与某些类型癌症的临床结局相关，但尚未在胃癌中进行研究。在本研究中，我们分析了II/III期胃癌患者中LMR与临床结局之间的关联。记录了426例II/III期胃癌患者外周血淋巴细胞和单核细胞计算出的术前LMR以及相应的临床特征。采用Kaplan-Meier法和Cox回归模型评估总生存期（OS）和无复发生存期（RFS）。LMR升高与较小的肿瘤大小相关（p<0.001），通过多变量分析，LMR升高可预测II/III期胃癌患者更好的OS [风险比（HR），0.688；95%置信区间（CI），0.521-0.908，p=0.008]，且与更好的RFS存在临界显著相关性（HR，0.775；95%CI，0.592-1.01，p=0.06）。亚组分析显示，除III期患者的RFS结果具有临界显著性（p=0.052）外，无论处于不同分期或是否接受辅助化疗，较低的LMR均与患者不良临床结局相关。术前LMR水平升高是II/III期胃癌患者预后的一个显著有利因素，尤其是II期患者。然而，我们的研究结果需要进一步验证。
